China SXT Pharmaceuticals annual gross margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
China SXT Pharmaceuticals Gross Margin Growth & History (SXTC)
China SXT Pharmaceuticals's gross margin was 21.85% for fiscal 2026.
View full China SXT Pharmaceuticals company overviewChina SXT Pharmaceuticals annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-31 | 21.85% | +0.75 pp |
| 2025 | 2025-03-31 | 21.11% | −7.62 pp |
| 2024 | 2024-03-31 | 28.73% | +7.11 pp |
| 2023 | 2023-03-31 | 21.62% | −26.48 pp |
| 2022 | 2022-03-31 | 48.10% | −11.34 pp |
| 2021 | 2021-03-31 | 59.43% | +7.06 pp |
| 2020 | 2020-03-31 | 52.37% | −13.39 pp |
| 2019 | 2019-03-31 | 65.77% | +17.31 pp |
| 2018 | 2018-03-31 | 48.46% | +1.10 pp |
| 2017 | 2017-03-31 | 47.36% | — |
China SXT Pharmaceuticals quarterly gross margin
No reported data
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|
China SXT Pharmaceuticals gross margin trends
Over the last five reported fiscal years, China SXT Pharmaceuticals's gross margin decreased from 59.43% to 21.85%, a change of −37.58 percentage points.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China SXT Pharmaceuticals filings at SEC.gov ↗